Download fulltext HTML
1.
Karimi S, Movafaghi V, Arabi A, Shahraki T, Safi S. Effects of Oral Vitamin D Supplement Therapy on Clinical Outcomes of Intravitreal Bevacizumab in Diabetic Macular Edema. JOVR [Internet]. 2021Jan.20 [cited 2024Apr.28];16(1):34–41. Available from: https://knepublishing.com/index.php/JOVR/article/view/8249

https://doi.org/10.18502/jovr.v16i1.8249

statistics

  • 775 Abstract Views
  • 610 PDF Views
  • 0 HTML Views
  • Cited by 1 article

authors

  • Saeed Karimi

    Saeed Karimi

    Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medicine Sciences, Tehran, Iran
  • Vahid Movafaghi

    Vahid Movafaghi

    Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medicine Sciences, Tehran, Iran
  • Amir Arabi

    Amir Arabi

    Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medicine Sciences, Tehran, Iran
  • Toktam Shahraki

    Toktam Shahraki

    Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medicine Sciences, Tehran, Iran
  • Sare Safi

    Sare Safi

    Ophthalmic Epidemiology Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medicine Sciences, Tehran, Iran

Published Date

  • Jan 20, 2021
This journal is publishing all the articles under Creative Commons Attribution License CC BY 4.0.

Effects of Oral Vitamin D Supplement Therapy on Clinical Outcomes of Intravitreal Bevacizumab in Diabetic Macular Edema

Journal of Ophthalmic and Vision Research (JOVR) / January–March 2021, Volume 16, Issue 1 / Pages 34–41

Abstract

Purpose: To assess the effects of oral vitamin D supplement therapy on clinical outcomes of intravitreal bevacizumab (IVB) injections in patients with diabetic macular edema (DME).


Method: Seventy-one patients with center-involving DME received IVB injections three times monthly. Cases with serum 25-hydroxyvitamin D (25(OH)D) levels <30 ng/ml were divided into treatment and control groups. The treatment group received 50000 IU of oral vitamin D once a week for eight weeks. One month after the third IVB injection, changes in the best-corrected visual acuity (BCVA) and central macular thickness (CMT) were analyzed for each group.


Results: Thirty-seven patients had sufficient levels of 25 (OH) D, while 34 patients had insufficient levels. Nineteen cases with deficient levels of 25(OH)D were treated with oral vitamin D, while 15 patients were assigned to the control group. The mean of serum 25(OH)D in patients was 27.9 ng/ml [mean 20.3 ± 5.4 and 17.3 ± 5.4 ng/ml in control and treatment groups, respectively (P = 0.231)]. After three IVB injections, BCVA improved significantly in each group, but the difference between the study groups was not statistically significant. CMT decreased significantly in all the groups. The mean CMT reduction was more prominent in the vitamin D-treated group, but the difference between groups did not reach statistical significance (P = 0.29).


Conclusion: In DME patients with vitamin D deficiency, vitamin D supplement therapy had some beneficial effects on CMT reduction following three injections of IVB; nevertheless, these effects were not statistically significant. Definite conclusion needs further prospective studies with a larger sample size.

Keywords:

25-Hydroxyvitamin D, Insufficiency, Diabetic Macular Edema, Intravitreal, Bevacizumab

References
1. Kim KL, Moon SY, Noh HM, Park SP, Kim YK. Serum and aqueous humor vitamin D levels in patients with diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 2019;257:1191–1198.

2. Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez- Galvez M, Navarro-Gil R, Verges R. Diabetic macular edema pathophysiology: vasogenic versus inflammatory. J Diabetes Res 2016;2016:2156273.

3. Diaz GD, Paraskeva C, Thomas MG, Binderup L, Hague A. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res 2000;60:2304–2312.

4. Jeong Y, Swami S, Krishnan AV, Williams JD, Martin S, Horst RL, et al. Inhibition of mouse breast tumor-initiating cells by calcitriol and dietary vitamin D. Mol Cancer Ther 2015;14:1951–1961.

5. Scaglione-Sewell BA, Bissonnette M, Skarosi S, Abraham C, Brasitus TA. A vitamin D3 analog induces a G1-phase arrest in CaCo-2 cells by inhibiting cdk2 and cdk6: roles of cyclin E, p21Waf1, and p27Kip1. Endocrinology 2000;141:3931–3939.

6. Iseki K, Tatsuta M, Uehara H, Iishi H, Yano H, Sakai N, et al. Inhibition of angiogenesis as a mechanism for inhibition by 1alpha-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int J Cancer 1999;81:730–733.

7. Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 2004;79:362–371.

8. Lin Y, Ubels JL, Schotanus MP, Yin Z, Pintea V, Hammock BD, et al. Enhancement of vitamin D metabolites in the eye following vitamin D3 supplementation and UV-B irradiation. Curr Eye Res 2012;37:871–878.

9. Albert DM, Scheef EA, Wang S, Mehraein F, Darjatmoko SR, Sorenson CM, et al. Calcitriol is a potent inhibitor of retinal neovascularization. Invest Ophthalmol Vis Sci 2007;48:2327–2334.

10. Alcubierre N, Valls J, Rubinat E, Cao G, Esquerda A, Traveset A, et al. Vitamin D deficiency is associated with the presence and severity of diabetic retinopathy in type 2 diabetes mellitus. J Diabetes Res 2015;2015:374178.

11. He R, Shen J, Liu F, Zeng H, Li L, Yu H, et al. Vitamin D deficiency increases the risk of retinopathy in Chinese patients with type 2 diabetes. Diabet Med 2014;31:1657–1664.

12. Wilkinson CP, Ferris F, Klein R, Lee P, Agardh C, Davis M, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003;110:1677–1682.

13. Jordan J, Ruiz-Moreno JM. Advances in the understanding of retinal drug disposition and the role of blood-ocular barrier transporters. Expert Opin Drug Metab Toxicol 2013;9:1181–1192.

14. Yin Z, Pintea V, Lin Y, Hammock BD, Watsky MA. Vitamin D enhances corneal epithelial barrier function. Invest Ophthalmol Vis Sci 2011;52:7359–7364.

15. Cardus A, Panizo S, Encinas M, Dolcet X, Gallego C, Aldea M, et al. 1,25-dihydroxyvitamin D3 regulates VEGF production through a vitamin D response element in the VEGF promoter. Atherosclerosis 2009;204:85–89.

16. Cardus A, Parisi E, Gallego C, Aldea M, Fernandez E, Valdivielso JM. 1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int 2006;69:1377–1384.

17. Millen AE, Sahli MW, Nie J, LaMonte MJ, Lutsey PL, Klein BE, et al. Adequate vitamin D status is associated with the reduced odds of prevalent diabetic retinopathy in African Americans and Caucasians. Cardiovasc Diabetol 2016;15:128.

18. Patrick PA, Visintainer PF, Shi Q, Weiss IA, Brand DA. Vitamin D and retinopathy in adults with diabetes mellitus. Arch Ophthalmol 2012;130:756–760.

19. Payne JF, Ray R, Watson DG, Delille C, Rimler E, Cleveland J, et al. Vitamin D insufficiency in diabetic retinopathy. Endocr Pract 2012;18:185–193.

20. Alam U, Amjad Y, Chan AW, Asghar O, Petropoulos IN, Malik RA. Vitamin D deficiency is not associated with diabetic retinopathy or maculopathy. J Diabetes Res 2016;2016:6156217.

21. Bonakdaran S, Shoeibi N. Is there any correlation between vitamin D insufficiency and diabetic retinopathy? Int J Ophthalmol 2015;8:326–331.

22. Luo BA, Gao F, Qin LL. The association between vitamin D deficiency and diabetic retinopathy in type 2 diabetes: a meta-analysis of observational studies. Nutrients 2017;9:307.

23. Mitri J, Muraru M, Pittas AG. Vitamin D and type 2 diabetes: a systematic review. Eur J Clin Nutr 2011;65:1005–1015.